Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.

被引：0
|
作者：
Kurbacher, Christian M.
Eichler, Christian A.
Quade, Annegret Barbara
Kunstmann, Gerhard
Herz, Susanne
Kurbacher, Jutta Anna
Warm, Mathias R.
机构：
[1] Gynecol Ctr Bonn Friedenspl, Bonn, Germany
[2] Krankenhaus Koln Holweide, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
597
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
    Bramwell, Vivien H. C.
    Doig, Gordon S.
    Tuck, Alan B.
    Wilson, Sylvia M.
    Tonkin, Katia S.
    Tomiak, Anna
    Perera, Francisco
    Vandenberg, Theodore A.
    Chambers, Ann F.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 503 - 511
  • [42] Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative,-Low, and-Positive Metastatic Breast Cancer
    Eisses, Bertha
    van Geel, Jasper J. L.
    Brouwers, Adrienne H.
    Bensch, Frederike
    Elias, Sjoerd G.
    Kuip, Evelien J. M.
    Jager, Agnes
    van der Vegt, Bert
    Lub-de Hooge, Marjolijn N.
    Emmering, Jasper
    Arens, Anne I. J.
    Zwezerijnen, Gerben J. C.
    Vugts, Danielle J.
    van Oordyt, C. Willemien Menke-van der Houven
    de Vries, Elisabeth G. E.
    Schroder, Carolina P.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (10) : 1540 - 1547
  • [43] Prospective evaluation of serum HER2 in comparison with HER2 expression on circulating tumor cells in metastatic breast cancer patients as part of the DETECT study
    Mueller, V.
    Riethdorf, S.
    Rack, B.
    Janni, W.
    Fasching, P.
    Gebauer, G.
    Solomayer, E.
    Aktas, B.
    Zeitz, J.
    Kasimir-Bauer, S.
    Fehm, T.
    ONKOLOGIE, 2010, 33 : 19 - 19
  • [44] Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
    Rodriguez Garces, Maria Yeray
    Fernandez Madrigal, Laura
    Morales Pancorbo, David
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [46] Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
    Batalha, Sofia
    Gomes, Catarina Monteiro
    Brito, Catarina
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [48] HER2 TUMOR HETEROGENEITY AND DISCREPANCIES IN HER2 STATUS BETWEEN PRIMARY TUMOR AND CORRESPONDING CIRCULATING TUMOR CELLS IN METASTATIC BREAST CANCER PATIENTS
    Migliaccio, I.
    Galardi, F.
    Bessi, S.
    Capaccioli, G.
    Biagioni, C.
    Truglia, M.
    Santarpia, L.
    Giannini, A.
    Di Leo, A.
    Pestrin, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 25 - 25
  • [49] Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.
    Mueller, Volkmar
    Riethdorf, Sabine
    Rack, Brigitte Kathrin
    Janni, Wolfgang
    Fasching, Peter A.
    Solomayer, Erich
    Aktas, Bahriye
    Kasimir-Bauer, Sabine
    Pantel, Klaus
    Fehm, Tanja N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
    Colomer, R
    Montero, S
    Lluch, A
    Ojeda, B
    Barnadas, A
    Casado, A
    Massutí, B
    Cortés-Funes, H
    Lloveras, B
    CLINICAL CANCER RESEARCH, 2000, 6 (06) : 2356 - 2362
12345